Camurus announced that the US FDA has accepted the resubmission of the New Drug Application (NDA) for CAM2029, an extended-release octreotide injection for treating acromegaly. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of December 18, 2026. This follows a previous Complete Response Letter related to manufacturing inspection issues, which have since been resolved without concerns about the drug's safety or efficacy. CAM2029 is already approved in the EU and UK and offers once-monthly self-administration via an autoinjector pen, with clinical trials showing superior biochemical control and improved patient outcomes compared to existing treatments. The FDA review outcome will determine its availability in the US market.
Netflix currently holds $27 billion in cash and resources earmarked for buying back its own stock, which represents roughly 8% of the company's total shares. This significant buyback capacity indicates Netflix's confidence in its valuation and a stra...
BP reported a strong second quarter with revenue up 29.2% and net profit soaring 193%, supported by high oil and refining margins. The company maintained stable operating expenses and generated significant cash flow, enabling faster-than-expected deb...
On September 18, 2026, US spot Bitcoin ETFs attracted $433 million in net inflows, while spot Ethereum ETFs gained $144 million, marking a rebound from previous mixed sessions. Fidelity led Bitcoin ETF inflows with $311 million, and BlackRock led Eth...
Bitcoin is moving away from a weakness zone and may enter a stronger bullish phase, according to CryptoQuant's analysis. Although the market has not yet experienced extreme speculative mania, Bitcoin's price rose 2.5% to $78,240.79, with indicators s...
XRP is approaching a significant technical breakout with a daily close above $1.55, completing an inverse head-and-shoulders pattern that signals a potential 35% rally toward $2. This pattern has been developing since summer, with strong buyer suppor...
